NANOG and Mobius syndrome: In summary, these data indicate that PDGFRs are downstream targets of TET1 and NANOG, their expression can be regulated by a TET1 inhibitor, and thus, TET1 is a potential therapeutic target to treat TET1-overexpressing MBs.